Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Summary

The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases. Due to the high prevalence of diabetes and because 30-40% of diabetic patients \[both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus\] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS), endothelin, and urotensin II are vasoactive hormones that have been extensively studied as other mediators although their relation to diabetic nephropathy is still speculative.

Timeline

Start

2022-12-20

Primary completion

2025-12-20

Completion

2025-12-20

Publications

• Rizk MA, El-Haggar SM, Ibrahim OM, Ghazi HA. Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial. J Diabetes Complications. 2025 Nov;39(11):109175. doi: 10.1016/j.jdiacomp.2025.109175. Epub 2025 Sep 10.

Drugs

Indications